oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Can probiotics modulate human disease by impacting intestinal barrier function?
NIZO Food Research, Ede, The Netherlands; BE-Basic Foundation, The Netherlands, Delft, The Netherlands.
Wageningen University, Host Microbe Interactomics Group, Wageningen, The Netherlands.
Örebro University, School of Medical Sciences. Örebro University Hospital.ORCID iD: 0000-0002-0362-0008
Metabolism and Nutrition Research Group, WELBIO – Walloon Excellence in Life Sciences and BIOtechnology, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Show others and affiliations
2017 (English)In: British Journal of Nutrition, ISSN 0007-1145, E-ISSN 1475-2662, Vol. 117, no 1, p. 93-107Article, review/survey (Refereed) Published
Abstract [en]

Intestinal barrier integrity is a prerequisite for homeostasis of mucosal function, which is balanced to maximise absorptive capacity, while maintaining efficient defensive reactions against chemical and microbial challenges. Evidence is mounting that disruption of epithelial barrier integrity is one of the major aetiological factors associated with several gastrointestinal diseases, including infection by pathogens, obesity and diabetes, necrotising enterocolitis, irritable bowel syndrome and inflammatory bowel disease. The notion that specific probiotic bacterial strains can affect barrier integrity fuelled research in which in vitro cell lines, animal models and clinical trials are used to assess whether probiotics can revert the diseased state back to homeostasis and health. This review catalogues and categorises the lines of evidence available in literature for the role of probiotics in epithelial integrity and, consequently, their beneficial effect for the reduction of gastrointestinal disease symptoms.

Place, publisher, year, edition, pages
Cambridge, United Kingdom: Cambridge University Press, 2017. Vol. 117, no 1, p. 93-107
Keywords [en]
Probiotics, Gut microbiota, Gut barrier, Immunity, Gastrointestinal disorders
National Category
Gastroenterology and Hepatology Nutrition and Dietetics
Identifiers
URN: urn:nbn:se:oru:diva-55041DOI: 10.1017/S0007114516004037ISI: 000395508700009PubMedID: 28102115Scopus ID: 2-s2.0-85009999827OAI: oai:DiVA.org:oru-55041DiVA, id: diva2:1080428
Note

Funding Agencies:

ILSI Europe Probiotic Task Force

FNRS

French Cancer Research Association (ARC)

Fonds de la Recherche Scientifique - FNRS  WELBIO-CR-2012S-02R

Funds InBev-Baillet Latour

ERC Starting Grant

European Research Council, Starting grant  336452-ENIGMO

Available from: 2017-03-10 Created: 2017-03-10 Last updated: 2018-07-30Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Brummer, Robert-Jan
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
British Journal of Nutrition
Gastroenterology and HepatologyNutrition and Dietetics

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 186 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf